IRVINE, Calif., April 23, 2014 /PRNewswire/ -- ChromaDex
Corp. (OTCQB: CDXC), an innovative natural products
company that provides proprietary, ingredients and science-based
solutions to the dietary supplement, food and beverage, animal
health, cosmetic and pharmaceutical industries, provided an update
today on its previously announced $62
million, four-year ingredient supply and brand licensing
agreement with 5LINX®, one of the largest and
fastest-growing direct marketing companies in the world.
5LINX® plans on launching several new innovative
health and wellness products that feature ChromaDex's recently
launched patented NIAGEN™ nicotinamide riboside (NR) and patented
PURENERGY® ingredients at its upcoming
international event in Atlantic City, NJ. The event will be
held May 14 to 17 and is expected to
be attended by thousands of 5LINX® sales
associates. ChromaDex's CEO and founder Frank L. Jaksch, Jr., will attend, and iconic
motivational speaker Tony Robbins
will be among those addressing the attendees.
Craig Jerabeck, CEO of
5LINX® commented, "The health and wellness story behind
NIAGEN™ nicotinamide riboside continues to grow, as numerous
favorable studies and articles have been published since this past
January when we decided to be among the first to offer dietary
supplements featuring NIAGEN™. Our level of enthusiasm and
anticipation continues to grow as we count down the days to our
annual event and the launch of our new line of products featuring
ChromaDex's patented ingredients."
Jaksch stated, "We are more convinced than ever that the network
marketing channel is ideal for the early development and adoption
of health and wellness products featuring our patented NIAGEN™ and
PURENERGY® ingredients. Our
interaction with the 5LINX® management team has been
outstanding. We will report in our 1st quarter
results meaningful revenue related to the 5LINX® deal,
and early indications are that 5LINX® will likely easily
exceed the first year minimum ingredient purchase requirements set
out in our agreement. I look forward to attending their
annual event in May in Atlantic
City and to being part of the celebrated launch of their
products featuring our ingredients."
In January 2014, 5LINX®
was granted marketing rights for ChromaDex's recently launched
patented NIAGEN™ nicotinamide riboside (NR) for use in dietary
supplements exclusively in the network marketing sales channel in
the United States, Canada and the Philippines. Under the
terms of the agreement, 5LINX® must purchase from
ChromaDex $2.1 million of NIAGEN™ in
2014, and an aggregate of $46 million
of NIAGEN™ from 2015 through 2017. NIAGEN™ is the first and
only commercially available brand of NR, which is found naturally
in trace amounts in milk and other foods and is a more potent,
no-flush version of niacin (vitamin B3). Published research has
shown that NR is perhaps the most potent precursor to NAD+ in the
mitochondria of animals. NAD+ is arguably the most important
cellular co-factor for improvement of mitochondrial performance and
energy metabolism.
5LINX® was also granted marketing rights for
ChromaDex's patented PURENERGY® ingredient
for use in dietary supplements, with select exclusivity in the
network marketing sales channel in the
United States, Canada and
Philippines. Under the exclusive network marketing channel
agreement, 5LINX® must purchase from ChromaDex
$520,000 of
PURENERGY® in 2014 and an aggregate of
$14 million of
PURENERGY® from 2015 through 2017.
ChromaDex's PURENERGY® innovative caffeine
ingredient is a patented co-crystal combination of caffeine and
ChromaDex's pTeroPure® pterostilbene, a potent anti-oxidant found
in blueberries. The first human study
of PURENERGY® demonstrated
PURENERGY® delivers 30 percent more
caffeine, stays in the blood stream longer, and is absorbed more
slowly than ordinary caffeine. With
PURENERGY® formulators of energy products
may have the ability to reduce the total amount of caffeine in
their products by as much as 50% without sacrificing consumers'
expectations from such products.
About Nicotinamide Riboside (NR):
Sometimes referred to as the "Miracle Molecule" or "Hidden
Vitamin," NR is found naturally in trace amounts in milk and other
foods and is a more potent, no-flush vitamin B3 (Niacin)
derivative.
Published research has shown that NR is perhaps the most
effective NAD+ booster, an essential metabolite found in all cells.
NAD+ is arguably the most important cellular co-factor for
improvement of mitochondrial performance and energy metabolism.
Mitochondria are the powerhouse of the cell where macronutrients
are converted to energy the cell can use. Mitochondria also play an
important part in the aging process. It is hoped that by
stimulating mitochondrial function with the NR molecule, scientists
may see increased longevity as well as other health improvements.
Researchers worldwide continue seminal discoveries characterizing
the unique properties of NR in a wide range of health benefits.
These include: increasing mitochondrial health, increasing muscle
endurance, neuroprotection, sirtuin activation, protection against
weight gain on high fat diet, protection against oxidative stress,
improvement of blood glucose and insulin sensitivity to maintain
blood sugar levels already within the normal range.
Findings from a recent study by Weill Cornell Medical
College and the Ecole Polytechnique Federale de Lausanne,
Switzerland researchers showed mice on a high-fat diet that
were fed NR gained 60 percent less weight than mice eating the same
high-fat diet without NR. Moreover, unlike the mice that were
not fed NR, none of the NR-treated mice had indications that they
were developing diabetes and they had improved energy and lower
cholesterol levels, all without side effects. The Swiss researchers
were quoted as saying the effects of NR on metabolism "are nothing
short of astonishing."
A study by researchers from Harvard Medical
School in conjunction with the National Institute on Aging was
published in December 2013 in CELL demonstrated
that mitochondrial dysfunction (a hallmark of aging) in aging mice
is due to a disruption in Sirtuin1-dependent nuclear-mitochondrial
communication. They further show that a reduction in NAD+ levels is
responsible for this disruption. Excitingly, they also show that
this mitochondrial dysfunction is readily reversible by
administration of a NAD+ precursor. The authors show that "1 week
of treatment with a compound that boosts NAD+ levels is sufficient
to restore the mitochondrial homeostasis and key biochemical
markers of muscle health in a 22-month-old mouse to levels similar
to a 6-month-old mouse."
About PURENERGY®:
ChromaDex's PURENERGY® is a novel,
patented next-generation caffeine ingredient derived from the
technology-driven fusion of caffeine and ChromaDex's patented
pTeroPure® pterostilbene. The first human study
of PURENERGY® demonstrated
PURENERGY® delivers 30% more caffeine,
stays in the blood stream longer, and is absorbed more slowly than
ordinary caffeine. With PURENERGY®
formulators of energy products may have the ability to reduce the
total amount of caffeine in their products by as much as 50%
without sacrificing consumers' expectations from such
products. Clinical studies show the ingredient provides a
rapid and sustained energy boost for at least 6 hours and the
potential for a more moderated and gradual finish, preventing the
"crash" experienced with caffeine products.
In addition to being a caffeine
alternative, PURENERGY® has
additional health benefits stemming from its co-crystal formulation
with pTeroPure® pterostilbene, which has shown great promise for
supporting heart health, cognitive function, anti-aging, weight
loss and other metabolic functions. pTeroPure® was named the 2010
North American Most Promising Ingredient of the Year by the
independent research company Frost & Sullivan.
About 5LINX®:
5LINX® offers a unique work from home business
opportunity based on essential products and services people use
every day. 5LINX® distributes its products and
services through a network of dedicated independent marketing
representatives. 5LINX® has earned the distinction as
being recognized by Inc. Magazine as one of the 5,000
fastest-growing privately-held companies in the country for the
last eight years. In 2011 and 2012, 5LINX® was named to the
Global 100 List compiled by Direct Selling News, the premier
direct sales industry magazine, making 5LINX® one of the
100 largest direct sales companies in the world.
About ChromaDex®:
ChromaDex is an innovative natural products company that
discovers, acquires, develops and commercializes proprietary-based
ingredient technologies through its unique business model that
utilizes its wholly owned synergistic business units, including
ingredient technologies, natural product fine chemicals (known as
"phytochemicals"), chemistry and analytical testing services, and
product regulatory and safety consulting (as Spherix Consulting).
The company provides seamless science-based solutions to the
nutritional supplement, food and beverage, animal health, cosmetic
and pharmaceutical industries. The ChromaDex ingredient
technologies unit includes products backed with extensive
scientific research and intellectual property. Its ingredient
portfolio includes pTeroPure® pterostilbene; ProC3G®, a
natural black rice containing cyanidin-3-glucoside;
PURENERGY® a
caffeine-pTeroPure® co-crystal; and NIAGEN™, its
recently launched branded nicotinamide riboside, a novel
next-generation B vitamin. To learn more about ChromaDex, visit
www.chromadex.com.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities and Exchange Act of
1934, as amended. Statements that are not a description of
historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects", "anticipates", "intends", "estimates", "plans",
"potential", "possible", "probable", "believes", "seeks", "may",
"will", "should", "could" or the negative of such terms or other
similar expressions. Actual results may differ materially from
those set forth in this release due to the risks and uncertainties
inherent in the Company's business. More detailed information about
the Company and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's Annual
Report on Form 10-K for the fiscal year ended December 28, 2013, the Company's Quarter Reports
on Form 10-Q and other filings submitted by the Company to the SEC,
copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement and the Company undertakes no
obligation to revise or update this release to reflect events or
circumstances after the date hereof.
ChromaDex Media Inquiries:
Beckerman PR
Jerry Schranz
201-465-8020
jschranz@beckermanpr.com
ChromaDex Company Contact:
Laura
Kelly, Executive Assistant
949-419-0288
laurak@chromadex.com
5LINX Company Contact:
William
Faucette, Jr.
Vice-President of North American Sales
585-576-4023
wfaucette@5linx.com
Statements in this press release have not been evaluated by
the Food and Drug Administration. Products or ingredients are
not intended to diagnose, treat, cure or prevent any
disease.
SOURCE ChromaDex Corp.